Paris, France, December 1, 2022 – 6:00 p.m. CET – Acticor Biotech (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biopharmaceutical company, spin-off from INSERM, developing an innovative drug for the treatment of cardiovascular emergencies, including accidents ischemic cerebrovascular diseases, today announces its financial agenda for the first half of 2023.
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]